TYK2 Inhibitors for the Management of Plaque Psoriasis:
Which of Your Patients May Benefit?
Podcast 1: Pretest

Questions marked with a * are required
100%
Contact Information
Deucravacitinib has shown a _____ fold selectively for _______ over other JAKs?
A 40 year old male has psoriasis on 25% of his body. He has lost efficacy to multiple biologics. What would be a possible treatment option for him?
Powered by QuestionPro